RxDoctor Payments Data

Joshua Mitchell, MD

Cardiovascular Disease · Saint Louis, MONPI 1871755470

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (57.8%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. 10 manufacturers reported payments, led by Pfizer at 57.7% of the total. 2025 is the largest year on record at $75,616, more than ten times the $6,650 reported in 2020. Among cardiovascular disease clinicians in MO with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$102,522in general payments, 2019–2025

Across 65 payments — averaging $1577.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$59K
  • Bridgebio Pharma, Inc.$24K
  • Alnylam Pharmaceuticals Inc.$8K
  • AstraZeneca$7K
  • Jazz Pharmaceuticals Inc.$3K
  • Altathera Pharmaceuticals LLC$600
  • plus $396 from 4 others
$1,293,881in research payments, 2019–2025

Across 125 payments — averaging $10,351 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • AstraZeneca$537K
  • Alnylam Pharmaceuticals Inc.$461K
  • Jazz Pharmaceuticals Inc.$122K
  • Astrazeneca UK Limited$54K
  • Myocardial Solutions, Inc.$45K
  • Abbott$44K
  • plus $31K from 3 others

What the payments were for

  • Consulting fees$59,30358%
  • Speaking & faculty fees$36,67336%
  • Travel & lodging$4,3564%
  • Food & beverage$2,1892%

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Pfizer32$59,202
Bridgebio Pharma, Inc.10$24,425
Alnylam Pharmaceuticals Inc.9$8,339
AstraZeneca(2 entities)7$6,636
Jazz Pharmaceuticals Inc.1$2,925
Altathera Pharmaceuticals LLC1$600
Elekta, Inc.1$140
Abiomed1$118
Myocardial Solutions, Inc.1$100
AbbVie2$37

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$102,522 in reported general payments places this provider in the 95th percentile of 391 cardiovascular disease providers in Missouri.

See all cardiovascular disease providers in Missouri

Medicare billing

Part B allowed, 2024
$201,492
Medicare patients
652
Services billed
4,571

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VyndamaxTafamidis209$4,893,058
VyndaqelTafamidis Meglumine104$2,404,093
EliquisApixaban334$338,328
EntrestoSacubitril/Valsartan254$249,154
JardianceEmpagliflozin242$225,528
FarxigaDapagliflozin Propanediol259$219,778
XareltoRivaroxaban63$69,628
Repatha SureclickEvolocumab29$24,328
OzempicSemaglutide22$20,554
DapagliflozinDapagliflozin Propanediol17$8,444
Eplerenone127$7,255
Telmisartan361$7,023
NexlizetBempedoic Acid/Ezetimibe13$5,427
Metoprolol Succinate395$4,634
Rosuvastatin Calcium487$4,009

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerVyndamax, Vyndaqel, Eliquis$59,202$7,635,479647 claims
AstraZenecaFarxiga$6,636$219,778259 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 391 cardiovascular disease providers in Missouri.

Other cardiovascular disease in Saint Louis

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →